Christopher Gaffney
YOU?
Author Swipe
View article: Supplemental Figure S5 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S5 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S5. Top differentially expressed genes by expression level and statistical significance.
View article: Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S3 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S3. Top differentially activated GO pathways with ADT.
View article: Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S4 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S4. GO Activated Immune Response Genes.
View article: Supplemental Figure S1 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S1 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S1. Sample clustering by RNAseq and top differentially expressed genes by treatment group.
View article: Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S6 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S6. Spatial proximity between immune cells and tumor cells.
View article: Data from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Data from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Purpose:Androgen deprivation therapy (ADT) remains the backbone of prostate cancer treatment. Beyond the suppression of testosterone and tumor cell growth, emerging evidence suggests that ADT also modulates the immune tumor microenvironmen…
View article: Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Supplemental Figure S2 from Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Open
Supplemental Figure S2. Differential expression of androgen-related genes with or without degarelix.
View article: Accelerating Drug Development in Hormone-Naïve Prostate Cancer and Changing the Paradigm from Palliation to Cure: The Metacure Phase 2 Randomized Clinical Trial
Accelerating Drug Development in Hormone-Naïve Prostate Cancer and Changing the Paradigm from Palliation to Cure: The Metacure Phase 2 Randomized Clinical Trial Open
View article: A brief mind-body intervention to reduce pain and anxiety during prostate needle biopsy: a clinically integrated randomized controlled trial with 2-staged consent
A brief mind-body intervention to reduce pain and anxiety during prostate needle biopsy: a clinically integrated randomized controlled trial with 2-staged consent Open
View article: Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma
Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma Open
View article: The oncologic risk of magnetic resonance imaging‐targeted and systematic cores in patients treated with radical prostatectomy
The oncologic risk of magnetic resonance imaging‐targeted and systematic cores in patients treated with radical prostatectomy Open
Background Magnetic resonance imaging (MRI)‐targeted prostate biopsy (MRI‐biopsy) detects high‐Grade Group (GG) prostate cancers not identified by systematic biopsy (S‐biopsy). However, questions have been raised whether cancers detected b…
View article: A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial
A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial Open
Background/Aims It has been proposed that informed consent for randomized trials should be split into two stages, with the purported advantage of decreased information overload and patient anxiety. We compared patient understanding, anxiet…
View article: Bladder Cancer Carcinogens: Opportunities for Risk Reduction
Bladder Cancer Carcinogens: Opportunities for Risk Reduction Open
View article: A multidisciplinary approach to optimize primary prostate cancer biobanking
A multidisciplinary approach to optimize primary prostate cancer biobanking Open
View article: Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity Open
View article: <i>SPOP</i>mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape
<i>SPOP</i>mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape Open
The normal androgen receptor (AR) cistrome and transcriptional program are fundamentally altered in prostate cancer (PCa). Here, we show that SPOP mutations, an early event in prostate tumorigenesis, reshape the chromatin landscape and AR-…
View article: Peyronie Disease
Peyronie Disease Open
Peyronie DiseasePeyronie disease is a common, treatable medical condition that affects millions of men in the US.
View article: Erectile Dysfunction is a Transient Complication of Prostate Biopsy: A Systematic Review and Meta-Analysis
Erectile Dysfunction is a Transient Complication of Prostate Biopsy: A Systematic Review and Meta-Analysis Open
Prostate biopsy does cause a mild, transient decrease in average IIEF-5 scores at 1-month post-biopsy. However, this resolves at 3 months on average, and average IIEF-5 remains at baseline at 6 months post-biopsy.
View article: Presentation and resolution of gender dysphoria as a positive symptom in a young schizophrenic man who presented with self‐emasculation: Frontiers of bioethics, psychiatry, and microsurgical genital reconstruction
Presentation and resolution of gender dysphoria as a positive symptom in a young schizophrenic man who presented with self‐emasculation: Frontiers of bioethics, psychiatry, and microsurgical genital reconstruction Open
Gender dysphoria can present as a positive symptom of schizophrenia. Completion of gender affirmation surgeries should not occur as a result of male genital self‐mutilation via a deferral of emergent surgical reconstruction. Instead, gende…
View article: Reply to The risk factors of upgrading in prostate cancer
Reply to The risk factors of upgrading in prostate cancer Open
Compared with standard biopsy, magnetic resonance imaging (MRI)–targeted prostate biopsy is superior in detecting high-risk prostate cancer1, 2 and is associated with lower rates of pathologic upgrading at the time of radical prostatectomy…
View article: Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance
Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance Open
Background Adoption of prostate magnetic resonance imaging (MRI) before biopsy is based on evidence demonstrating superior detection of clinically significant prostate cancer on biopsy. Whether this is due to the detection of otherwise occ…
View article: MP51-03 PROSTATE TUMOR SIZE IS INDEPENDENTLY ASSOCIATED WITH GENOMIC RISK
MP51-03 PROSTATE TUMOR SIZE IS INDEPENDENTLY ASSOCIATED WITH GENOMIC RISK Open
You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology II (MP51)1 Apr 2020MP51-03 PROSTATE TUMOR SIZE IS INDEPENDENTLY ASSOCIATED WITH GENOMIC RISK Christopher Gaffney*, Deli Liu, Cynthia Angulo, Peter Cai, Simp…
View article: MP42-18 INCREASING UTILIZATION OF MAGNETIC RESONANCE IMAGING (MRI) PRIOR TO PROSTATE BIOPSY IN BLACK AND NON-BLACK MEN: AN ANALYSIS OF THE SEER-MEDICARE COHORT
MP42-18 INCREASING UTILIZATION OF MAGNETIC RESONANCE IMAGING (MRI) PRIOR TO PROSTATE BIOPSY IN BLACK AND NON-BLACK MEN: AN ANALYSIS OF THE SEER-MEDICARE COHORT Open
You have accessJournal of UrologyImaging/Radiology: Uroradiology II (MP42)1 Apr 2020MP42-18 INCREASING UTILIZATION OF MAGNETIC RESONANCE IMAGING (MRI) PRIOR TO PROSTATE BIOPSY IN BLACK AND NON-BLACK MEN: AN ANALYSIS OF THE SEER-MEDICARE CO…
View article: Risk Factors for Infection after Prostate Biopsy in the United States
Risk Factors for Infection after Prostate Biopsy in the United States Open
View article: Postorgasmic illness syndrome: potential new treatment options for a rare disorder
Postorgasmic illness syndrome: potential new treatment options for a rare disorder Open
A new device for ex-vivo perfusion of kidneys is presented. When used in alteration with hypothermic machine preservation, it was shown to improve kidney function in a four-day autotransplant and contralateral nephrectomy model.
View article: Magnetic resonance and computed tomography imaging features of epithelioid sarcoma in children and young adults with pathological and clinical correlation: a report from Children’s Oncology Group study ARST0332
Magnetic resonance and computed tomography imaging features of epithelioid sarcoma in children and young adults with pathological and clinical correlation: a report from Children’s Oncology Group study ARST0332 Open
View article: Lengthening strategies for Peyronie’s disease
Lengthening strategies for Peyronie’s disease Open
Loss of penile length is a common complaint of men with Peyronie's disease (PD), both before and after corrective intervention, which has a significant negative effect on patient quality of life. We sought to identify and describe the meth…